
Biotech 2050 Podcast
Liam Killingstad on How Family Offices Quietly Fuel Biotech’s Boldest Innovations
Mar 6, 2025
Liam Killingstad, co-founder of KHORA Therapeutics and Operating Partner at Finiam Investments, dives into the transformative role of family offices in biotech. He shares how personal experiences with rare cancers ignited a mission-driven investment approach. The conversation uncovers the unique strategies family offices employ, their agile funding capabilities, and the impact of tailored investments on biotech innovation. Liam also reflects on his journey from investment banking to biotech, highlighting the essential skills required to bridge these industries effectively.
59:19
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Family offices' unique investment strategies are tailored to long-term familial goals, allowing them discretion in navigating high-stakes biotech investments.
- Personal experiences, such as hereditary cancer, drive family offices to invest in biotech, fostering deep industry connections and market understanding.
Deep dives
Understanding Family Offices
Family offices, representing either single or multiple families, are unique investment entities that do not conform to standardized definitions. Their strategies, asset management structures, and investment objectives can vary significantly, sometimes making it challenging for outsiders to understand their approaches. Investments can be crafted to align with a family's long-term goals, lifestyle choices, or even charitable aspirations. Ultimately, these offices operate with a level of discretion and customizability that differentiates them from traditional investment vehicles.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.